JPH08504214A - 放出調整賦形剤として容易に入手できるコンニャクグルコマンナン - Google Patents
放出調整賦形剤として容易に入手できるコンニャクグルコマンナンInfo
- Publication number
- JPH08504214A JPH08504214A JP6515521A JP51552194A JPH08504214A JP H08504214 A JPH08504214 A JP H08504214A JP 6515521 A JP6515521 A JP 6515521A JP 51552194 A JP51552194 A JP 51552194A JP H08504214 A JPH08504214 A JP H08504214A
- Authority
- JP
- Japan
- Prior art keywords
- konjac
- solid dosage
- dosage form
- xanthan gum
- range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920002752 Konjac Polymers 0.000 title claims abstract description 133
- 235000010485 konjac Nutrition 0.000 title claims abstract description 132
- 241001312219 Amorphophallus konjac Species 0.000 title claims abstract description 110
- 235000001206 Amorphophallus rivieri Nutrition 0.000 title claims abstract description 110
- 239000000252 konjac Substances 0.000 title claims abstract description 109
- 229920002581 Glucomannan Polymers 0.000 title claims abstract description 29
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 title claims abstract description 28
- 229940046240 glucomannan Drugs 0.000 title claims abstract description 28
- 239000000546 pharmaceutical excipient Substances 0.000 title claims abstract description 23
- 239000007909 solid dosage form Substances 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 229920003023 plastic Polymers 0.000 claims abstract description 10
- 239000004033 plastic Substances 0.000 claims abstract description 10
- 230000000144 pharmacologic effect Effects 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 29
- 239000000843 powder Substances 0.000 claims description 28
- 239000000230 xanthan gum Substances 0.000 claims description 22
- 229920001285 xanthan gum Polymers 0.000 claims description 22
- 229940082509 xanthan gum Drugs 0.000 claims description 22
- 235000010493 xanthan gum Nutrition 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 8
- 238000007906 compression Methods 0.000 claims description 2
- 230000006835 compression Effects 0.000 claims description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 2
- 239000002831 pharmacologic agent Substances 0.000 claims 2
- 239000008196 pharmacological composition Substances 0.000 claims 2
- 238000007907 direct compression Methods 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 229940075420 xanthine Drugs 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 71
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 62
- 229960000278 theophylline Drugs 0.000 description 31
- 235000013312 flour Nutrition 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 239000008367 deionised water Substances 0.000 description 22
- 229910021641 deionized water Inorganic materials 0.000 description 22
- 239000000499 gel Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 230000001186 cumulative effect Effects 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 238000007922 dissolution test Methods 0.000 description 10
- 238000013270 controlled release Methods 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- -1 Glucomannan hydrates Chemical class 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 230000036571 hydration Effects 0.000 description 5
- 238000006703 hydration reaction Methods 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000945 filler Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000007912 modified release tablet Substances 0.000 description 4
- 239000012736 aqueous medium Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000005352 clarification Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920003094 Methocel™ K4M Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003139 biocide Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000002363 herbicidal effect Effects 0.000 description 2
- 239000004009 herbicide Substances 0.000 description 2
- 239000000416 hydrocolloid Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004080 punching Methods 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- WYUYEJNGHIOFOC-VVTVMFAVSA-N 2-[(z)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C\CN1CCCC1 WYUYEJNGHIOFOC-VVTVMFAVSA-N 0.000 description 1
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 239000004484 Briquette Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940057282 albuterol sulfate Drugs 0.000 description 1
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011805 ball Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000004512 die casting Methods 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- MZNZKBJIWPGRID-UHFFFAOYSA-N diphenylphosphorylmethyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)CP(C=1C=CC=CC=1)C1=CC=CC=C1 MZNZKBJIWPGRID-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960004842 ephedrine sulfate Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 229960002146 guaifenesin Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- PGYPOBZJRVSMDS-UHFFFAOYSA-N loperamide hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 PGYPOBZJRVSMDS-UHFFFAOYSA-N 0.000 description 1
- 229960002983 loperamide hydrochloride Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 229960002790 phenytoin sodium Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 1
- 229960002244 promethazine hydrochloride Drugs 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229960004604 propranolol hydrochloride Drugs 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol hydrochloride Natural products C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960004482 quinidine sulfate Drugs 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229940000044 respiratory system drug Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000009490 roller compaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229960001593 triprolidine hydrochloride Drugs 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.固体投与形態の重量に基づいて、活性成分及び少なくとも7重量%の容易に 入手できるコンニャクグルコマンナン薬剤放出調整賦形剤を含むことを特徴とす る固体投与形態。 2.コンニャクグルコマンナン薬剤放出調整賦形剤の量が7%から50%である ことを特徴とする請求項1記載の固体投与形態。 3.コンニャクグルコマンナン薬剤放出調整賦形剤の量が10%から40%であ ることを特徴とする請求項1記載の固体投与形態。 4.さらにキサンタンガムを含み、そして容易に入手できるコンニャクグルコマ ンナンとキサンタンガムとの重量比が20:1から1:1であることを特徴とす る請求項1記載の固体投与形態。 5.固体投与形態が、pHが1から7.4の範囲内で3時間から12時間の範囲 内の薬剤放出時間を有することを特徴とする請求項4記載の固体投与形態。 6.さらにキサンタンガムを含み、そしてpHが1から7.4の範囲内で、容易 に入手できるコンニャクグルコマンナンとキサンタンガムとの重量比が20:1 から1:1であることを特徴とする請求項3記載の固体投与形態。 7.さらにキサンタンガムを含み、そして容易に入手できるコンニャクグルコマ ンナンとキサンタンガムとの重量比が15:1から5:1であり、そしてpHが 1から7.4の範囲内で薬剤放出時間が3時間から12時間の範囲内であること を特徴とする請求項2記載の固体投与形態。 8.さらにキサンタンガムを含み、そして容易に入手できるコンニャクグルコマ ンナンとキサンタンガムとの重量比が12:1から6:1であることを特徴とす る請求項2記載の固体投与形態。 9.さらにキサンタンガムを含み、そして素早く水和するコンニャ ク薬剤放出調整賦形剤とキサンタンガムとの比が12:1から6:1の範囲内で あり、そして薬剤放出時間が3時間から10時間の範囲内であることを特徴とす る請求項3記載の固体投与形態。 10.容易に入手できるコンニャクグルコマンナンが、透明コンニャク、極低温 粉砕コンニャク、及び可塑性コンニャクよりなる群から選ばれたものであること を特徴とする請求項1記載の固体投与形態。 11.容易に入手できるコンニャクグルコマンナンが、透明コンニャク、極低温 粉砕コンニャク、及び可塑性コンニャクよりなる群から選ばれたものであること を特徴とする請求項4記載の固体投与形態。 12.容易に入手できるコンニャクグルコマンナンが、透明コンニャク、極低温 粉砕コンニャク、及び可塑性コンニャクよりなる群から選ばれたものであること を特徴とする請求項3記載の固体投与形態。 13.錠剤の形態である請求項1から12のいずれかに記載の固体投与形態。 14.活性成分が薬理学的に活性な成分であり、そして固体投与形態が錠剤であ ることを特徴とする請求項1から12のいずれかに記載の固体投与形態。 15.乾燥した、少なくとも7重量%の乾燥した、容易に入手できるコンニャク グルコマンナン薬剤放出調整賦形剤と薬理学的に活性な成分の混合物を形成し、 また6kgの硬さをもつ錠剤を形成するに十分な圧力でその混合物を圧縮する工 程を特徴とする薬理学的な錠剤製造法。 16.容易に入手できるコンニャクグルコマンナン賦形剤が7から50重量%の 範囲内であることを特徴とする請求項15記載の製造法。 17.8から14kgの範囲内の硬さをもつ錠剤を形成するに十分な圧力で直接 圧縮することを特徴とする請求項16記載の製造法。 18.直接圧縮工程の前に、キサンチンガムと容易に入手できるコンニャクグル コマンナンを20:1から1:20の比で混合することを含むことを特徴とする 請求項17記載の製造法。 19.容易に入手できるコンニャクグルコマンナンとキサンタンガムとの比が6 :1から12:1の範囲内であることを特徴とする請求項18記載の製造法。 20.容易に入手できるコンニャクグルコマンナンが透明コンニャク、極低温粉 砕コンニャク、及び可塑性コンニャクよりなる群から選ばれたものであることを 特徴とする請求項17記載の薬理学的組成物製造法。 21.容易に入手できるコンニャクグルコマンナンが透明コンニャク、極低温粉 砕コンニャク、及び可塑性コンニャクよりなる群から選ばれたものであることを 特徴とする請求項19記載の薬理学的組成物製造法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99833592A | 1992-12-30 | 1992-12-30 | |
| US998,335 | 1992-12-30 | ||
| PCT/US1993/011970 WO1994015643A1 (en) | 1992-12-30 | 1993-12-09 | Readily available konjac glucomannan sustained release excipient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH08504214A true JPH08504214A (ja) | 1996-05-07 |
| JP2628231B2 JP2628231B2 (ja) | 1997-07-09 |
Family
ID=25545069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6515521A Expired - Lifetime JP2628231B2 (ja) | 1992-12-30 | 1993-12-09 | 放出調整賦形剤として容易に入手できるコンニャクグルコマンナン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5486364A (ja) |
| EP (1) | EP0676967A4 (ja) |
| JP (1) | JP2628231B2 (ja) |
| AU (1) | AU5745394A (ja) |
| CA (1) | CA2152795C (ja) |
| MX (1) | MX9308188A (ja) |
| WO (1) | WO1994015643A1 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013103922A (ja) * | 2011-11-16 | 2013-05-30 | Shimizu Kagaku Kk | 徐放性組成物 |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1172429A (zh) * | 1994-12-01 | 1998-02-04 | 希博斯药物公司 | 使用从高等植物中可得到的粉末状水解胶体树胶的持续释放药物运送体系 |
| EP0804169A4 (en) * | 1994-12-01 | 1998-08-19 | Cibus Pharmaceutical Inc | NSAID ADMINISTRATION USING A POWDERED HYDROCOLLOID GUM MACHINABLE FROM HIGHER PLANTS |
| FR2729857B1 (fr) * | 1995-01-27 | 1997-04-04 | Rhone Poulenc Chimie | Compositions pharmaceutiques sous forme de comprimes a liberation prolongee a base de granules en polysaccharides de haut poids moleculaire |
| US5811388A (en) * | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
| US6893664B1 (en) * | 1996-06-17 | 2005-05-17 | Powderject Research Limited | Particle delivery techniques |
| GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| JPH10114682A (ja) * | 1996-10-11 | 1998-05-06 | Shimizu Kagaku Kk | グルコマンナン配合持効性内服用薬剤 |
| US6537318B1 (en) * | 1998-04-06 | 2003-03-25 | Konjac Technologies, Llc | Use of glucomannan hydrocolloid as filler material in prostheses |
| US6497157B1 (en) * | 1999-11-29 | 2002-12-24 | Distek, Inc. | Intrinsic dissolution apparatus with stationary sample holder |
| US8012504B2 (en) * | 2000-04-28 | 2011-09-06 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
| US7838032B2 (en) * | 2000-04-28 | 2010-11-23 | Reckitt Benckiser Inc. | Sustained release of guaifenesin |
| US6955821B2 (en) | 2000-04-28 | 2005-10-18 | Adams Laboratories, Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
| US7985420B2 (en) * | 2000-04-28 | 2011-07-26 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
| US7326404B2 (en) * | 2000-05-31 | 2008-02-05 | Vuksan Holdings Inc. | Konjac-mannan and ginseng compositions and methods and uses thereof |
| SE0003125D0 (sv) * | 2000-09-05 | 2000-09-05 | Astrazeneca Ab | Modified polymers |
| EP1501498B1 (en) * | 2002-04-26 | 2009-12-30 | F. Hoffmann-La Roche Ag | Pharmaceutical composition comprising a lipase inhibitor and glucomannan |
| DE10247910A1 (de) * | 2002-10-14 | 2004-04-22 | Beisel, Günther | Mittel zur Erzeugung eines langanhaltenden Sättigungseffektes |
| US8003152B1 (en) * | 2006-03-30 | 2011-08-23 | Vitalico LLC | Fast-hydratable konjac composition |
| JP5323834B2 (ja) | 2007-08-17 | 2013-10-23 | エルジー・ライフ・サイエンシーズ・リミテッド | 細胞壊死阻害剤としてのインドール化合物 |
| CN101780400B (zh) * | 2009-01-21 | 2011-11-09 | 西南科技大学 | 热塑性葡甘聚糖阳离子吸附材料及其制备方法 |
| CA2791206A1 (en) * | 2012-09-28 | 2014-03-28 | Pharmascience Inc. | Abuse deterrent pharmaceutical formulation |
| US9114091B2 (en) | 2013-07-05 | 2015-08-25 | Shimizu Chemical Corporation | Sustained release solid dosage preparations |
| EP2826464A1 (en) * | 2013-07-19 | 2015-01-21 | Shimizu Chemical Corporation | Sustained release solid dosage preparations |
| HUE065006T2 (hu) | 2014-07-03 | 2024-04-28 | SpecGx LLC | Nem-cellulóz poliszacharidokat tartalmazó, visszaélés-gátló, azonnali felszabadulású készítmények |
| GB201506755D0 (en) | 2015-04-21 | 2015-06-03 | Reckitt Benckiser Llc | Novel pharmaceutical formulation |
| US11278506B2 (en) | 2015-10-09 | 2022-03-22 | Rb Health (Us) Llc | Pharmaceutical formulation |
| WO2018195271A1 (en) * | 2017-04-20 | 2018-10-25 | Dow Global Technologies Llc | Fast hydratable konjac flour |
| WO2018195267A1 (en) | 2017-04-20 | 2018-10-25 | Dow Global Technologies Llc | Fast hydratable konjac flour |
| CN112739724A (zh) | 2018-07-23 | 2021-04-30 | 纽崔吉诺姆有限责任公司 | 在含水系统中产生和维持分子氢(h2)的组合物和方法 |
| WO2020068510A1 (en) | 2018-09-25 | 2020-04-02 | SpecGx LLC | Abuse deterrent immediate release capsule dosage forms |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901111A (fr) * | 1943-08-31 | 1945-07-18 | Perfectionnement aux dispositifs de réglage de terrage des charruesbascules | |
| US3928322A (en) * | 1970-12-30 | 1975-12-23 | Shimizu Manzo Shoten Kk | Konjac mannan |
| JPS57185216A (en) * | 1981-05-11 | 1982-11-15 | Chiyoda Yakuhin Kk | Preparation of glucomannan tablet |
| FR2523446A1 (fr) * | 1982-03-19 | 1983-09-23 | Dietlin Francois | Nouveau procede d'obtention de formes pharmaceutiques a liberation programmee |
| FR2531339A1 (fr) * | 1982-08-04 | 1984-02-10 | Dietlin Francois | Nouveau procede d'obtention de formes pharmaceutiques a liberation programmee |
| JPS60219238A (ja) * | 1984-04-14 | 1985-11-01 | Hayashibara Biochem Lab Inc | 徐崩性プルラン含有成形物とその製法 |
| BE901111A (fr) * | 1984-11-22 | 1985-03-15 | Benfar Representee Par Vanderl | Composition pharmaceutiques a liberation prolongee, leur procede de preparation et leur utilisation. |
| GB8431699D0 (en) * | 1984-12-14 | 1985-01-30 | Mars G B Ltd | Gel system |
| GB8601204D0 (en) * | 1986-01-18 | 1986-02-19 | Boots Co Plc | Therapeutic agents |
| GB8616669D0 (en) * | 1986-07-09 | 1986-08-13 | Merk Sharpe & Dohme Ltd | Pharmaceutical compositions |
| GB8710704D0 (en) * | 1987-05-06 | 1987-06-10 | Mars G B Ltd | Edible gels |
| US4994276A (en) * | 1988-09-19 | 1991-02-19 | Edward Mendell Co., Inc. | Directly compressible sustained release excipient |
| US5096714A (en) * | 1988-06-28 | 1992-03-17 | Hauser-Kuhrts, Inc. | Prolonged release drug tablet formulations |
| JPH0443819A (ja) * | 1990-06-09 | 1992-02-13 | Yamaha Motor Co Ltd | 2サイクルエンジンの吸気用ロータリバルブ装置 |
-
1993
- 1993-12-09 EP EP94903550A patent/EP0676967A4/en not_active Withdrawn
- 1993-12-09 JP JP6515521A patent/JP2628231B2/ja not_active Expired - Lifetime
- 1993-12-09 CA CA002152795A patent/CA2152795C/en not_active Expired - Fee Related
- 1993-12-09 AU AU57453/94A patent/AU5745394A/en not_active Abandoned
- 1993-12-09 WO PCT/US1993/011970 patent/WO1994015643A1/en not_active Ceased
- 1993-12-17 MX MX9308188A patent/MX9308188A/es not_active Application Discontinuation
-
1994
- 1994-08-15 US US08/290,457 patent/US5486364A/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013103922A (ja) * | 2011-11-16 | 2013-05-30 | Shimizu Kagaku Kk | 徐放性組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0676967A4 (en) | 1996-10-02 |
| CA2152795A1 (en) | 1994-07-21 |
| JP2628231B2 (ja) | 1997-07-09 |
| CA2152795C (en) | 1999-02-16 |
| AU5745394A (en) | 1994-08-15 |
| WO1994015643A1 (en) | 1994-07-21 |
| US5486364A (en) | 1996-01-23 |
| EP0676967A1 (en) | 1995-10-18 |
| MX9308188A (es) | 1994-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2628231B2 (ja) | 放出調整賦形剤として容易に入手できるコンニャクグルコマンナン | |
| DE60120413T2 (de) | Quervernetzte stark amylose haltige stärke zur verwendung in pharmazeutischen formulierungen mit kontrollierter freisetzung und verfahren zu ihrer herstellung | |
| El-Kamel et al. | Chitosan and sodium alginate—Based bioadhesive vaginal tablets | |
| DE68907835T2 (de) | Direkt verpressbare Füllstoffe zur verzögerten Freisetzung. | |
| DE60026357T2 (de) | An- und abschwellende polymermischungen | |
| JPH06500576A (ja) | 制御解放ベラパミルタブレット | |
| JP5934812B2 (ja) | 制御放出の製剤処方または食品処方およびその製造方法 | |
| JPH08507769A (ja) | 錠剤のバインダー/崩壊剤としての架橋アミロース | |
| DE69429964T2 (de) | Feste, therapeutische oder hygienische, mucoadhäsive Zusammensetzung zur Verabreichung durch Auftragen auf der Mund-schleimhaut oder der Nasen-schleimhaut | |
| EP1198227A1 (de) | Verfahren zur herstellung schnell zerfallender, fester pharmazeutischer zubereitungen | |
| DE69935609T2 (de) | Formulierungen enthaltend cefuroxim-axetil | |
| DE69119217T2 (de) | Zusammensetzungen zur kontrollierten freigabe | |
| AU581177B2 (en) | Dry direct compression compositions for controlled release dosage forms | |
| ES2369868T3 (es) | Formulación de liberación lenta basada en una asociación de glucógeno y alginato. | |
| JP3319625B2 (ja) | 速崩壊性生薬製剤 | |
| US6649191B1 (en) | Orally administrable compositions comprising cation cross-linked polysaccharide and a polymer digestible in the lower gastrointestinal tract | |
| TWI236913B (en) | Hydrolyzed cellulose granulations of salts of drugs | |
| DE602004008737T2 (de) | Chondroitinsulfat enthaltende Zusammensetzung | |
| ES2246961T3 (es) | Excipiente de liberacion sostenida. | |
| US4086335A (en) | Pharmaceutical tablets containing chitin as a disintegrant | |
| JPH10509982A (ja) | 高等植物から獲得できる粉末ヒドロコロイドゴムを利用するnsaidの導入 | |
| EP3222270B1 (en) | Compositions for mucosal adhesion and uses thereof | |
| JPH10502937A (ja) | フシジン酸錠剤の製法 | |
| JPH0418036A (ja) | 薬剤組成物 | |
| Rahi | Review Article on Superdisintegrants Agents Used in Formulations of Sublingual Tablets. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FPAY | Renewal fee payment |
Free format text: PAYMENT UNTIL: 20080213 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment |
Year of fee payment: 5 Free format text: PAYMENT UNTIL: 20090213 |
|
| FPAY | Renewal fee payment |
Free format text: PAYMENT UNTIL: 20090213 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment |
Free format text: PAYMENT UNTIL: 20100213 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment |
Free format text: PAYMENT UNTIL: 20110213 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment |
Free format text: PAYMENT UNTIL: 20110213 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment |
Free format text: PAYMENT UNTIL: 20120213 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment |
Year of fee payment: 9 Free format text: PAYMENT UNTIL: 20130213 |
|
| FPAY | Renewal fee payment |
Free format text: PAYMENT UNTIL: 20130213 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment |
Free format text: PAYMENT UNTIL: 20130213 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment |
Free format text: PAYMENT UNTIL: 20130213 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment |
Year of fee payment: 9 Free format text: PAYMENT UNTIL: 20130213 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| FPAY | Renewal fee payment |
Free format text: PAYMENT UNTIL: 20130213 Year of fee payment: 9 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |